Barclays Maintains an 'Equalweight' on Medtronic (MDT); INFUSE in Focus at NASS

November 7, 2011 3:18 PM EST
Get Alerts MDT Hot Sheet
Price: $93.35 +1.14%

Rating Summary:
    25 Buy, 18 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Medtronic, Inc. (NYSE: MDT) price target of $38.00.

Barclays analyst says, "Of the "hot topics" in spine at the North American Spine Society Meeting (Nov 2-5) we thought that there was the most buzz around biologics and BMP, as the subject came up in all of our meetings. In general, our perception is that BMP is being used less (either in less cases or smaller doses in cases) with some hospitals apparently restricting the use of BMP in spine cases altogether. We think that lower BMP use is likely being replaced by other biologics including NuVasive (Nasdaq: NUVA) OsteoCel, but to a greater extent other cheaper alternatives including allograft."

For more ratings news on Medtronic, Inc. click here and for the rating history of Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $34.38 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Barclays